– Total Revenues increased 33.0% for the quarter over the prior year period to $68.8 million – – Organic Revenue Growth Rate* of 11.7% for the quarter – – Net income of $14.4 million for the quarter – – Adjusted EBITDA* increased 56.9% for the quarter over the prior year period to $21.7 million - – Share Repurchase Authorization approved for up to $50 million - THE WOODLANDS, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- TWFG, Inc. (“TWFG”, the “Company” or “we”) (NASDAQ: TWFG), a high-growth insurance distribut ...

Haleon shares fall 3.4% as revenue growth falls short of the company's own medium-term target Proactive uses images sourced from Shutterstock A weak cold and flu season and a cautious American consumer pushed organic growth to 3%, a full percentage point below the floor of what Haleon has promised investors Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 3.4% to 392.1p on Wednesday after the consumer health group reported full-year organic revenue growth of 3%, missing the 4-6% medium-term range it has set as i ...

2025 Full year results February 2026 Disclaimer This presentation contains certain statements that are, or may be deemed to be, "forward-looking statements" (including for purposes of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements give Haleon's current expectations and projections about future events, including strategic initiatives and future financial condit ...

Infusion Care: Organic growth was 12.5%. Ryder said demand in diabetes remained strong as automated insulin delivery penetration increased, while non-diabetes growth was led by infusion sets for AbbVie’s Parkinson’s disease therapy. Other therapies rose to 15% of infusion care revenue, up from about 10% in 2024.Continence Care: Organic growth was 6.6%, driven by higher U.S. volumes and a growing mix of ConvaTec-branded products. Hydrophilic products were again more than 60% of the category’s revenue, and in ...

Core Insights - Nilfisk demonstrated resilience in a challenging macroeconomic environment, achieving organic growth of 0.2% in 2025 and improving its cost position significantly [1][3] Financial Performance - Revenue for 2025 was reported at 996.3 million EUR, reflecting a decline of 3.1% due to negative foreign exchange effects and the divestment of the US high-pressure washer business [2][3] - The gross margin stood at 42.0%, slightly down from 42.2% in 2024, impacted by increased tariffs but supported by operational improvements [2][4] - EBITDA before special items was 129.2 million EUR, with an EBITDA margin of 13.0%, down from 13.6% in the previous year [2][4] - Operating profit (EBIT) before special items was 67.4 million EUR, with an EBIT margin of 6.8%, compared to 7.4% in 2024 [2] Regional Performance - EMEA and APAC regions reported positive organic growth of 2.3% and 3.9%, respectively, driven by strong commercial execution and market share gains [5] - The Americas region faced challenges with organic growth of -4.9%, primarily due to a negative backlog effect, although adjusted growth was 4.9% when accounting for this backlog [5] Strategic Initiatives - The company continued to implement structural efficiency initiatives, including production consolidations and cost reduction programs, leading to a more competitive cost base [6] - Ongoing discipline in working capital and strategic portfolio actions, such as the divestment of the US high-pressure washer business, are expected to enhance financial resilience and positively impact emissions [6] Future Outlook - For 2026, Nilfisk anticipates organic revenue growth between -1% and 2%, with an EBIT margin before special items projected to be in the range of 7.0% to 9.0% [7]

Core Viewpoint - Medtronic plc reported fiscal third-quarter 2026 results that exceeded analyst expectations, although shares experienced a decline of over 2% intra-day following the release [1] Financial Performance - The company generated revenue of $9.0 billion, reflecting an 8.7% increase on a reported basis and 6.0% organic growth year over year, surpassing the consensus estimate of $8.89 billion [2] - Adjusted earnings per share were reported at $1.36, slightly above expectations of $1.34 [2] - The quarter marked the strongest enterprise revenue growth for the company in 10 quarters [2] Segment Performance - The Cardiovascular Portfolio led the performance with revenue climbing 13.8% as reported and 10.6% organically to $3.46 billion, with Cardiac Ablation Solutions showing particularly strong results, including an 80% increase in global revenue and a 137% surge in U.S. revenue [3] - Other segments also reported gains: the Neuroscience Portfolio increased 4.1% to $2.56 billion, the Medical Surgical Portfolio rose 4.9% to $2.17 billion, and the Diabetes segment grew 14.8% to $796 million [4] Outlook - Medtronic reaffirmed its fiscal 2026 outlook, maintaining expectations for approximately 5.5% organic revenue growth and adjusted EPS between $5.62 and $5.66, which includes a potential $185 million headwind from tariffs [4]

PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS) Transformative year leading to a materially enhanced strategic platformOrder intake up over 180%, supported by c.€1 bn firm order through OCCARRevenue and Adj. EBIT up c. 26% and 28% respectively vs FY 2024, with Adj. EBIT margin >26%Have entered 2026 with strong momentum from structural growth trends, historically high backlog and expanded product portfolioSmall bolt-on M&A envisaged in FY 2026 without the need for a new Share Capital Increase 16 Feb ...

Core Viewpoint - Analysts forecast Omnicom (OMC) will report quarterly earnings of $2.72 per share, reflecting a year-over-year increase of 12.9%, with anticipated revenues of $4.5 billion, up 4.2% from the previous year [1] Earnings Projections - The consensus EPS estimate has been revised downward by 7% in the past 30 days, indicating a reassessment by covering analysts [2] - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3] Revenue Estimates - Analysts expect 'Revenue- Commerce & Branding' to be $176.75 million, a decrease of 9.1% from the prior-year quarter [4] - The estimate for 'Revenue- Execution & Support' is $215.42 million, indicating a 1.7% increase year-over-year [5] - 'Revenue- Healthcare' is projected at $293.75 million, reflecting a decline of 13.4% year-over-year [5] - 'Revenue- Public Relations' is expected to be $454.59 million, showing a slight decrease of 0.4% from the previous year [5] Geographic Revenue Insights - 'Revenue by Geography- Asia Pacific' is estimated to reach $543.15 million, a year-over-year increase of 3.9% [6] - 'Revenue by Geography- Middle East and Africa' is projected at $102.47 million, indicating a decline of 7.4% from the prior-year quarter [6] - 'Revenue by Geography- North America' is expected to be $2.38 billion, reflecting a 3% increase year-over-year [7] - 'Revenue by Geography- Latin America' is forecasted to reach $135.63 million, suggesting a 3.5% increase year-over-year [7] Organic Revenue Growth - Total Organic Revenue Growth is projected at 2.4%, down from 5.2% reported in the same quarter last year [7] - 'Organic Revenue Growth - Experiential' is expected to be -2.3%, compared to 4.9% in the previous year [8] - 'Organic Revenue Growth - Precision Marketing' stands at 3.2%, down from 9.1% year-over-year [8] - 'Organic Revenue Growth - Advertising & Media' is estimated at 6.4%, slightly lower than the 7.1% reported last year [9] Stock Performance - Over the past month, Omnicom shares have declined by 13.5%, contrasting with the Zacks S&P 500 composite's decline of 1.7% [9] - Based on its Zacks Rank 3 (Hold), Omnicom is expected to perform in line with the overall market in the upcoming period [10]

Q4 2025 Earnings Results February 12, 2026 1 Legal Disclaimer This presentation and the accompanying conference call contain forward-looking statements within the meaning of the federal securities laws, including statements about our future performance and goals. These statements involve substantial risks and uncertainties that may cause our actual results, performance or achievement to differ materially, as further described in the Appendix, as well as in our most recent periodic reports filed with the SEC ...

Financial Data and Key Metrics Changes - In FY 2025, the company achieved a total revenue growth of 12% and an organic revenue growth of 8%, excluding a confidential contract [4][22] - Adjusted EBITDA expanded by 60 basis points to a record margin of 9.6%, building on a previous expansion of 50 basis points in 2024 [4][24] - Free cash flow conversion reached 100%, exceeding the high end of FY 2025 cash flow guidance [4][22] Business Line Data and Key Metrics Changes - Critical Infrastructure segment reported 10% organic growth, while Federal Solutions segment achieved 7% organic growth, both excluding the confidential contract [4] - In Q4, Critical Infrastructure revenue increased by 12% year-over-year, driven by organic growth of 9% and contributions from recent acquisitions [25] - Federal Solutions segment saw a 9% increase in revenue for Q4, with a 6% organic growth, but total revenue including the confidential contract decreased by 22% [27] Market Data and Key Metrics Changes - The company reported strong demand in both North America and Middle East markets, with double-digit revenue growth in both regions [16][19] - The backlog at the end of Q4 totaled $8.7 billion, with a funded backlog of $6.4 billion, representing the highest level since the IPO [31] Company Strategy and Development Direction - The company aims to achieve mid-single digit or better annual organic revenue growth supplemented by accretive acquisitions, targeting double-digit margins by 2028 [8][32] - The focus remains on integrated solutions to move up the value chain and win larger, more strategic programs [7][19] - The company is well-positioned to capitalize on unprecedented global infrastructure spending and a favorable federal budget environment [18][34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing a robust pipeline of opportunities and strong total and funded backlog [36][37] - The company anticipates a positive procurement environment in Federal Solutions, with expectations of achieving a book-to-bill ratio over 1.0 in H1 2026 [44][65] Other Important Information - The company completed three acquisitions in FY 2025 and has a strong balance sheet with a net debt leverage ratio of 1.3 times [29][30] - The acquisition of Applied Sciences Consulting and Altamira Technologies Corporation is expected to enhance the company's capabilities and market presence [14][15] Q&A Session Summary Question: Expectations for Critical Infrastructure margins - Management confirmed that legacy adjustments are behind them and expects continued margin expansion in Critical Infrastructure, with a focus on North America [40] Question: Order activity in Federal Solutions post-government shutdown - Management noted a positive trend in order activity and anticipates achieving a book-to-bill ratio over 1.0 in H1 2026 [44] Question: Addressable market for DroneArmor system - Management highlighted the unique capabilities of the DroneArmor solution and its potential applications across various federal departments [50] Question: Demand for mega projects in the Middle East - Management reported ongoing strong demand for major projects in the Middle East, particularly in Saudi Arabia, with a focus on key upcoming global events [54] Question: Federal Solutions revenue guidance adjustments - Management acknowledged previous revenue guidance revisions due to procurement delays and expressed confidence in a positive procurement environment moving forward [64] Question: Margin outlook and potential for upside - Management indicated that while there are headwinds from a confidential program, there are opportunities for margin expansion through product growth and accretive M&A [72]